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Received 14 October 2009; accepted 2 September 2010AbstractBackground: To examine the prevalence of microalbuminuria (MAU) and chronic kidney disease as well as the correlation between MAU and
renal and cardiovascular risks of Type 2 diabetes mellitus (T2DM) patients for public health policy making in Taiwan.
Methods: This was a multicenter, hospital-based, randomly selected, and cross-sectional study. T2DM patients aged 18e80 years without
a known diagnosis of proteinuria were eligible. MAU was defined as urinary albumin-to-creatinine ratio (ACR) within 30e299 mg/g, and
macroalbuminuria as that greater than or equal to 300 mg/g. Two positive out of three urinary screening results were required to make the
diagnosis of MAU. The adjusted prevalence of MAU was calculated by conditional probability approach.
Results: 51.1% of the analyzed population (n¼ 1,827) were women, with a mean (standard deviation) age of 59.16 years (11.19 years) and mean
hemoglobin A1c (HbA1c) of 8.15% (1.83%). Median duration of DM history was 6 years (interquartile range, 3e11 years). The adjusted
prevalence of MAU was 26.9%. Overall prevalence of chronic kidney disease Stage 3 or higher (estimated Glomerular filtration rate (eGFR) less
than 60/mL/min/1.73 m2) was 13.8%. Only 4.7% of the T2DM patients had serum albumin test recorded and 68.7% with serum creatinine test
recorded within the last 6 months. After adjustment for center and gender, the odds ratios for MAU or macroalbuminuria were 1.73 (95% CI,* The authors have no conflict of interest to declare.
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4 S.-C. Chiang et al. / Journal of the Chinese Medical Association 74 (2011) 3e101.27e2.36) for age greater than or equal to 60 years, 1.54 (1.13e2.10) for abnormal waist circumference, 1.10 (1.02e1.19) for every 1%
increase in hemoglobin A1c, 1.91 (1.38e2.65) for higher systolic blood pressure, and 1.92 (1.19e3.07) for abnormal serum creatinine level.
Conclusion: This study demonstrates the application of “conditional probability” method to justify the rationale of adopting two positive out of
three urinary screening tests for the diagnosis of MAU. An adjusted prevalence rate of MAU as 26.9% is reported. These results may provide
a basis for costebenefit consideration in designing preventive and interventional policies in public health. Furthermore, the awareness and
practice of early monitoring of MAU for DM patients should be strengthened.
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Microalbuminuria (MAU) has been reported as an impor-
tant risk factor for the progression of renal and cardiovascular
diseases in diabetes mellitus (DM) patients since 1974.1,2 In
2003, the guidelines of the American Diabetes Association
(ADA) recommended annual screening of MAU to be per-
formed in diabetic patients.3 The Chinese Taipei Diabetes
Association4 also announced its recommendation to adopt
ADA standards. High prevalence of MAU in Type 2 DM
(T2DM) patients has been reported in Asia. According to the
Microalbuminuria Asian Prevalence Study, the prevalence of
MAU was reported as 39.8% and macroalbuminuria as 18.8%
in Asian population. In this survey, around 40% of the patients
screened in Taiwan had MAU.5 The Developing Education on
MAU for Awareness of reNal and cardiovascular risk in Dia-
betes (DEMAND) Study reported similar prevalences (43%
for MAU and 12% for proteinuria) in Asia and approximately
61.7% for MAU in Taiwanese population,2 which seemed to
be the highest in the region. Therapeutic intervention has
proven to be effective in slowing the progression to overt
nephropathy.6 It is, therefore, critically important to identify
kidney disease at the earliest stage to delay the evolution to
overt nephropathy and its subsequent risk of end-stage renal
disease, particularly in T2DM patients.
The main objective of this study was to further confirm the
prevalence of MAU in Taiwan and to evaluate the correlation
between MAU and other well-known renal and cardiovascular
risk factors. Through the understanding of the local disease
community, it is our ultimate goal to increase physician aware-
ness, by medical education, on the importance of annual urinary
albumin screening in T2DM patients to improve patients’
quality of care and make public health policy in Taiwan.
2. Methods2.1. Patients and study design
The 1st
test 
The 2nd
test 
The 3rd
test 
MAU 
Result 
Fig. 1. The major process for urine sample screening. Note: means that there
is no follow-up urine test (missing).T2DM patients who visited outpatient clinics in the 11
participating tertiary medical centers in Taiwan were the target
of the survey population. Random tables with selecting marks
were provided to all participating hospitals, and two out of
every 10 sequential T2DM patients were randomly selected
from each physician’s clinic.
The inclusion criteria for the selected T2DM patients were
age between 18 and 80 years and no known diagnosis ofproteinuria or acute fever. Female patients who were pregnant
or in menstruation period were excluded.
Three urine screening tests were performed within 6
months after inclusion. At the first screening visit, demo-
graphic and the following information were collected from the
medical records: DM, hypertension and cardiovascular disease
history, drug treatment records, and biochemical laboratory
data in the last 6 months before the first visit date.
The major process of urine screening was as follows. In the
beginning, every patient took the first urine screening; if the
result from the first screening was positive for MAU or mac-
roalbuminuria, a second follow-up screening should be done
within the coming 3 months. Unless the second result was also
positive, the third follow-up screening should again be done
within the next 3 months from the second visit date (Fig. 1).
Two additional processes were designed to provide further
information for conditional probability approach. One process
was that patients completed the first and second screenings
within 3 months from the date of first visit; if the results from
these two screenings were different and could not determine
the final MAU status, then a third follow-up screening should
be done within the next 3 months. Two centers executed this
process. The other process was that each patient had to
complete all the three urinary screenings. One center executed
the last kind of process. The diagnosis of MAU was defined as
two positive out of three urinary screening results.2.2. AssaysIn each screening, a random urine specimen was used to
measure albumin-to-creatinine ratio (ACR). The urine albumin
and creatinine levels were tested by a commercial dipstick,
Microalbustix (Microalbustix Bayer, Bridgend, UK). This test
provided semi-quantitative results with 89% accuracy, 90%
sensitivity, and 88% specificity for albumin, and 88% accuracy,
84% sensitivity, and 91% specificity for ACR (information
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creatinine level less than 10 mg/dL were considered as over-
diluted and were tested twice. If both results were the same,
10 mg/dL for creatinine level was used to measure the ACR.
MAU and macroalbuminuria were defined as having ACR
within 30e299 mg/g and greater than or equal to 300 mg/g,
respectively. Proteinuriawas tested byUristix (Bayer, Bridgend,
UK). The accuracy, sensitivity, and specificity of ACR
measurement by Microalbustix dipstick was verified using
radioimmunoassay as standard on 11 patients. The results were
81.8%, 100%, and 60%, respectively.2.3. PopulationsThe study was conducted from March 1, 2005, to February
9, 2006, with a total of 56 physicians from 11 medical centers
participating. Out of 2,730 randomly selected patients, 1,924
were eligible for enrollment. The survey protocol was
approved by the Joint Institutional Review Board in Taiwan,7
and informed consent was obtained from each patient. The
screening failure rate was 29.5%: 11.0% because of known or
new diagnosis of proteinuria, 2.3% for age violation, 11.9%
for patient disagreement, and 4.3% for other reasons. In detail,
out of 1,924 eligible participants, 1,111 patients had only the
first urine test result, 574 had both the first and second test
results, and 239 had all the three urine test results. Ninety-
seven patients were lost to follow-up, which makes a total per-
protocol analyzed population of 1,827 patients. Figure 2
illustrates the patient enrollment status.2.4. Statistical methodsPopulation characteristics were summarized into mean,
standard deviation (SD), or median for quantitative variables
and count, percentage for categorical data. The crude preva-
lences of MAU and macroalbuminuria were reported globally.
The final prevalence of MAU was provided by the conditional
probability approach for missing adjustment. Student’s t-test
was used to compare quantitative variables and Chi-squared
test or Fisher’s exact test for categorical variables. Then = 12,621 patients with 13,837 visits
n = 2,730 patients 
n = 1,924 patients 
n = 1,827 patients 
Eligible enrollment
Randomly selected
participants
Outpatient listing 
Per-protocol population 
Screening failure rate: 29.5%
For (1) known /new PAU (2) Age > 80 
(3) No intention to participate
Dropout rate:
5.0%
Fig. 2. Patient disposition and enrollment flow chart.KaplaneMeier method was used to estimate the age and DM
duration of the 25th-percentile or median MAU cumulative
incidence. Multivariate logistic regression was used to eval-
uate the risk factors of MAU or macroalbuminuria. A p value
less than 0.05 was considered statistically significant. All
statistical analyses were performed by SAS version 9.0 (SAS
Institute, Cary, NC, USA).
The principle of probability calculation under the conditional
probability approach was similar to the serial screening test in
disease screening. As Fig. 1 illustrates, when the first screen test
was negative, there would be no second and third tests, and
these patients were counted as “missing.” By the additional two
screening processes, the data of patients who completed at least
two screening tests were used to estimate the probability of each
possible outcome of the second screening, given the first
screening result, and the data of patients who completed all the
three screening tests were used to estimate the probability of
each possible outcome of the third screening, given the first and
second screening results. Then, the final outcome probability
could be calculated by multiplying the third screening proba-
bility with the given condition probability. Finally, we added up
the probabilities of all possible final outcomes that indicated
the diagnosis of MAU as the so-called “the adjusted preva-
lence,” as Table 1 demonstrates. The gray cells in Table 1 show
that the probability, unreasonably affected by the sparse count
of the third screening, had been corrected by contingency factor
or the estimation from the second screening.
3. Results3.1. Patient characteristicsMean and SD of age were 59.16 years and 11.19 years,
respectively. The odds for men and women were 48.9% versus
51.1%. The means (SD) for weight, waist circumference, and
body mass index were 65.97 kg (12.1 kg), 87.95 cm (10.7 cm),
and 25.65 kg/m2 (4.1 kg/m2), respectively. Mean (SD) of
HbA1c was 8.15% (1.83%), systolic blood pressure (SBP) was
131.64 mmHg (17.0 mmHg), and diastolic blood pressure was
76.67 mmHg (10.9 mmHg). Median duration of DM history
was 6 years, with interquartile range of 3e11 years.3.2. Prevalence of MAUThe prevalence of MAU was 19.2% (351 out of 1,827), with
a 95% confidence interval (CI) of 17.4e21.0%. The adjusted
prevalence of MAU was 26.9% by conditional probability
approach, as shown in Table 1. Based on these MAU results of
239 patients who completed three screening tests, the false-
negative (FN) rate of the first screening test was found to be
5.84%, and the false-positive (FP) rate was found to be 65.7%
(67 out of 102). By conditional probability approach, the FN
rate rose to 6.87% and FP rate went down to 5.55%.
According to the classic epidemiological method, using the
age structure of Taiwan population in December 2005 as
standard, the age-adjusted prevalence was 11.1%. By
KaplaneMeier method, the age of 25th-percentile MAU
Table 1
The micro- and macroalbuminuria prevalence counted by conditional probability
First screening Second screening Third screening Final outcome
Finalc Diagnosis Total
Codea Freq Prob(f) Code Freq Prob(s j f) Code Freq Prob(t j f&s) Code Prob(f_s_t)d Result Probability
N(f) 1,924 N(sj f)b 345 N(tj f&s) 120
0 1,396 0.7256 0 280 0.8116 0 112 0.9333 000 0.5496 Normo-AU
1 7 0.0583 001 0.0344 Normo-AU
2 1 0.0083 002 0.0049 Normo-AU
N(tj f&s) 15.5 Normo-AU
1 61 0.1768 0 8 0.5161 010 0.0662 Normo-AU 0.7122
1 7 0.4516 011 0.0579 Micro-AU
2 0.5 0.0323 012 0.0041 Micro-AU
N(tj f&s) 2
2 4 0.0116 0 1 0.2027 020 0.0017 Normo-AU
1 1 0.5270 021 0.0044 Micro-AU
2 0 0.2703 022 0.0023 Macro-AU
N(sj f) 393 N(tj f&s) 73
1 446 0.2318 0 108 0.2748 0 56 0.7671 100 0.0489 Normo-AU
1 14 0.1918 101 0.0122 Micro-AU
2 3 0.0411 102 0.0026 Micro-AU
N(tj f&s) 13 Micro-AU
1 262 0.6667 0 2 0.1538 110 0.0238 Micro-AU 0.2687
1 7 0.5385 111 0.0832 Micro-AU
2 4 0.3077 112 0.0476 Micro-AU
N(tj f&s) 2
2 23 0.0585 0 1 0.2027 120 0.0027 Micro-AU
1 0 0.5270 121 0.0071 Micro-AU
2 1 0.2703 122 0.0037 Macro-AU
N(sj f) 74 N(tj f&s) 14.5
2 82 0.0426 0 15 0.2027 0 11 0.7586 200 0.0066 Normo-AU
1 3 0.2069 201 0.0018 Micro-AU
2 0.5 0.0345 202 0.0003 Macro-AU
N(tj f&s) 0 Macro-AU
1 39 0.5270 0 0 0.2748 210 0.0062 Micro-AU 0.0191
1 0 0.6667 211 0.0150 Micro-AU
2 0 0.0585 212 0.0013 Macro-AU
N(tj f&s) 0
2 20 0.2703 0 0 0.2027 220 0.0023 Macro-AU
1 0 0.5270 221 0.0061 Macro-AU
2 0 0.2703 222 0.0031 Macro-AU
The code f¼ the first, s¼ the second, and t¼ the third screening, e.g. Prob(s¼ 0jf¼ 0)¼N(s¼ 0jf¼ 0)/N(s¼ 0,1,2 and f¼ 0)¼ 280/345¼ 0.816.
Macro-AU¼macroalbuminuria; Micro-AU¼microalbuminuria; Normo-AU¼ normoalbuminuria.
The gray cells show that the probability, unreasonably affected by the sparse count of the third screening, had been corrected by contingency factor or the
estimation from the second screening.
a Code value: 0¼ normoalbuminuria, 1¼microalbuminuria, and 2¼macroalbuminuria.
b N(sj f)¼ the total frequency of all possible outcomes for the second test, given the specific outcome of the first test.
c Final code: 012 means the outcomes of the three screenings were normoalbuminuria for the first, microalbuminuria for the second, and macroalbuminuria for
the third, and so forth.
d Prob(f_s_t)¼ Prob(t j f&s) Prob(s j f) Prob(f).
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duration of median MAU cumulative incidence was 23 years
(Fig. 3A and B).3.3. Risk factor evaluationTable 2 compares the results of demographic variables
between the MAU and normoalbuminuria groups. The MAU
patients were older and had greater weight, larger waistcircumference, higher body mass index, worse HbA1c control,
and higher SBP.
MAU patients had a mean (SD) duration of 8.5 years (6.7
years) of DM history, longer than that of normoalbuminuria
patients, and also had greater percentage of retinopathy
complication (28.9% vs. 21.5%, p¼ 0.003). Concerning
drug therapies, 82.2% of MAU patients were treated with
oral antidiabetic agents, 9.2%, 7.5%, and 1.2% for insulin
alone, oral antidiabetic agents plus insulin, and no drug
AB
(yr)
(yr)
C
C
Fig. 3. (A) Cumulative incidence of microalbuminuria (MAU) plotted against
age. (B) Cumulative incidence of microalbuminuria plotted against diabetes
mellitus (DM) duration.
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and 4.1%, respectively, in normoalbuminuria patients
( p¼ 0.006).
The T2DMpatients with a history of hypertension weremore
likely to have MAU compared with those without hypertension
(56% vs. 44%, p¼ 0.004). MAU patients had statistically sig-
nificant higher SBP (134.5 mmHg vs.130.8 mmHg, p< 0.001).
For those 951 (52.6%) T2DM patients with hypertension
history, totally 816 (85.8%) received antihypertensive drug
treatment: 59.2% patients had a single drug, 27.9% had two-
drug combination, and 12.9% had three or more drug combi-
nation treatment; on average, 1.5 drugs were used per patient.
Most of the prescriptions were for angiotensin receptor blockers
(ARB) (39.0%), followed by calcium channel blockers (35.4%),angiotensin-converting enzyme (ACE) inhibitors (31.1%),
beta blockers (22.7%), diuretics (21.7%), and alpha blockers
(5.0%). Excluding three patients with ARB and ACE combined
therapy, the association between MAU or macroalbuminuria
and antihypertension drug (ACE only/combination vs. ARB
only/combination vs. other drugs only/combination without
ACE or ARB) was not statistically significant ( p¼ 0.614). The
percentages ofMAU in the drug groups were 18.7%, 22.2%, and
23.48%, respectively.
Data on seven laboratory parameters measured in the latest 6
months before enrollmentdblood urea nitrogen, creatinine,
albumin, triglycerides, high-density-lipoprotein cholesterol, low-
density-lipoprotein cholesterol, and uric aciddwere recorded
and evaluated for their possible associationwithMAU.Validity of
laboratory data was highest for triglycerides (73.9%) and lowest
for albumin (4.7%). Thus, among the MAU-related laboratory
parameters, only 4.7% of the T2DM patients had serum albumin
test recorded and 68.7% with serum creatinine test recorded
within the latest 6 months. This information indicated rela-
tively low awareness of chronic kidney disease (CKD) either in
patients or physicians. Based on these limited data,MAUpatients
showed statistically significant mean difference from normoal-
buminuria patients in terms of blood urea nitrogen, creatinine,
high-density-lipoprotein cholesterol, and low-density-lipoprotein
cholesterol (Table 2).
For the covariate-adjusted multivariate analysis, Table 3
presents the final result of multivariate logistic regression.
As only 66.5% of the patients had serum creatinine measured,
the effective sample size for Model 2 was lowered to 1,181.
We found that the estimated odds ratios were very similar and
consistent between these two models. The continuous vari-
ables were categorized for interpretation.
Based on Model 2, after adjustment for center, gender, and
diastolic blood pressure, the patients older than 60 years had
an odds ratio of 1.73 (95% CI, 1.26e2.36) of having MAU or
macroalbuminuria compared with those who were younger
than 60 years. The odds ratios (95% CIs) for MAU or mac-
roalbuminuria were 1.1 (1.02e1.2) for every 1% HbA1c
increase, 1.54 (1.13e2.10) for abnormal waist circumference,
1.91 (1.37e2.65) for higher SBP, and 1.92 (1.20e3.07) for
abnormal serum creatinine level.
There were 13.7% (171 out of 1,246 patients with eligible
data) of patients found with CKD Stage 3 or higher (estimated
GFR less than 60/mL/min/1.73 m2) in this study. Partitioned
into normoalbuminuria, MAU, and macroalbuminuria, 11.2%,
22.4%, and 29.4% of patients, respectively, were found with
CKD Stage 3 or higher. Patients with CKD Stage 3 or higher
had a higher rate of MAU or macroalbuminuria (36.3%; 62 out
of 171) compared with patients with CKD Stage less than 3
(19.4%; 209 out of 1,075)dp< 0.001.
4. Discussion
MAU prevalences reported in the DEMAND Study were
39% globally and 43% in Asia versus only 26.9% in our study,
which used a more concise and conservative diagnostic defi-
nition. “Transient physiological proteinuria,” such as that after
Table 2
The comparison among micro-, macro-, and normoalbuminuria patients
Total (n¼1,827) Normoalbuminuria
(n¼1,455)
Microalbuminuria (n¼351) Macroalbuminuria (n¼21)
n Mean SD Mean SD pa Mean SD pb
Age (yr) 1,820 58.51 11.08 61.74 11.02 <0.0001 61.14 14.97 <0.0001
Gender 1,820
Female 930 735 (50.8%) 180 (51.3%) 0.861 15 (71.43%) 0.169
Male 890 713 (49.2%) 171 (48.7%) 6 (28.57%)
Height (cm) 1,824 160.25 8.75 160.38 8.86 0.214 157.1 8.78 0.136
Weight (kg) 1,825 65.64 11.73 67.67 13.28 0.009 60.63 10.32 0.002
Waist (cm) 1,816 87.60 10.49 89.45 11.29 0.005 87.34 10.11 0.014
BMI (kg/m2) 1,823 25.48 3.90 26.43 4.74 0.001 24.57 3.43 0.000
HbAlc (%) 1,713 8.09 1.81 8.35 1.81 0.020 9.28 2.92 0.002
SBP (mmHg) 1,825 130.82 16.65 134.53 17.73 0.000 140 23.67 <0.0001
DBP (mmHg) 1,825 76.57 10.67 77.02 11.57 0.505 77.81 11.57 0.696
Urine Cr (mg/dL) 1,827 118.0 80.8 104.6 68.6 Nullc 16.2 21.1 Null
Urine Alb (mg/L) 1,827 17.7 14.6 56.9 33.9 Null 59.1 43.6 Null
Alb/Cr ratio 1,827 25.4 34.2 102.9 166.1 Null 520.5 398.8 Null
BUN (mg/dL) 301 16.56 7.85 19.49 8.62 0.009 17.72 3.59 0.033
Cr (mg/dL) 1,257 0.91 0.31 0.99 0.39 0.002 1.05 0.36 0.001
Albumin (g/dL) 84 4.09 0.70 4.10 0.68 0.975 4.30 0.26 0.880
TG (mg/dL) 1,362 143.64 99.94 140.94 84.01 0.650 199 118.9 0.049
HDL-c (mg/dL) 1,074 46.35 13.77 43.47 14.01 0.007 47.53 13.26 0.022
LDL-c (mg/dL) 900 115.44 34.01 122.00 34.81 0.018 130.44 35.16 0.019
UA (mg/dL) 512 5.83 1.79 6.01 1.71 0.348 5.71 1.90 0.624
AU¼ albuminuria; Alb¼ albumin; BMI¼ body mass index; BUN¼ blood urea nitrogen; Cr¼ serum creatinine; DBP¼ diastolic blood pressure; HDL-c¼ high-
density-lipoprotein cholesterol; LDL-c¼ low-density-lipoprotein cholesterol; SBP¼ systolic blood pressure; SD¼ standard deviation; TG¼ triglycerides;
UA¼ uric acid.
a The p value of t-test/Chi-squared test for normoalbuminuria and microalbuminuria comparison.
b The p value of analysis of variance/Chi-squared test for the comparison of three groups.
c Null means that no statistical testing was done, because urine Cr and urine Alb were the components of Alb/Cr ratio.
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Authors of the DEMAND Study admitted three limitations
in their study, which were single random urine collection,
nonpersistent MAU definition, and possible selection bias.
These limitations were virtually avoided in our study, which
may contribute to the relatively low MAU prevalence found.
The cumulative risk effect of age and DM duration
described a very different pattern. For every 1-year increase in
DM duration, there was a nearly constant risk of developing
MAU, whereas for age, the risk effect rose sharply after 60Table 3
The multivariate logistic regression of micro- and macroalbuminuria
Variables Model 1a
OR 95% CI
Age (＞60 vs. 60) 1.70 1.31 2.19
Gender (female vs. male) 0.93 0.72 1.20
Waist (abnormal vs. normal)b 1.52 1.17 1.97
HbA1c (per 1%) 1.12 1.05 1.20
SBP (＞130 vs. 130) 1.68 1.27 2.22
DBP (＞80 vs. 80) 0.85 0.63 1.15
Creatinine (abnormal vs. normal)c
Effective n 1,685
CI¼ confidence interval; DBP¼ diastolic blood pressure; OR¼ odds ratio; SBP¼
a The two models have adjusted center effect.
b Abnormal waist circumference: ＞80 cm for females and ＞90 cm for males.
c Abnormal creatinine level: ＞1.4 mg/dL for females and ＞1.5 mg/dL for malyears of age. Using multivariate logistic regression, there was
a 1.022-fold risk for every 1-year increase in DM duration (the
estimated odds ratio was 1.022 with 95% CI of 1.004e1.040,
after adjusting for center and gender effect). Therefore,
a policy of yearly screening of MAU is recommended once the
diagnosis of diabetes is made and even more often for patients
older than 60 years (e.g. every 6 months).
Concerning the screening methodology (two out of three
determinations for the MAU diagnosis standard), the condi-
tional probability approach provided an estimate for theModel 2a
p OR 95% CI p
0.000 1.73 1.27 2.36 0.000
0.554 1.06 0.76 1.46 0.747
0.002 1.54 1.13 2.10 0.006
0.001 1.10 1.02 1.19 0.017
0.000 1.91 1.37 2.65 0.000
0.295 0.95 0.66 1.35 0.775
1.97 1.19 3.07 0.007
1,181
systolic blood pressure.
es.
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patients with the first MAU testing had 66.7% chance to get
the second MAU diagnosis, and the same interpretation can be
made for the other conditional probabilities in Table 1. Added
up, the three concordant pairs of the first and second screening
results had 69.2% agreement in this study. In the Shanghai
study, this agreement was reported to be 73.3% for the first
versus the second screening.9 In clinical practice, the esti-
mated probability in Table 1 can be used to identify the high-
risk MAU patients with noncompliant screening, because
around 7.0% of patients may have negative result at the first
screening followed by two positive results for MAU in the
subsequent two screenings. Thus, it is still worth completing
all three screening tests within 6 months when the first
screening shows normoalbuminuria. Because of the limitations
of our study, further study is needed to figure out the risk
parameters for FN patients in the first MAU screening test.
Recently, several articles reported the MAU prevalence in
Asian countries. MAU was found in 41.4% of T2DM pop-
ulation in Shanghai, China, and in 13.7% of the Japanese
general population.10 Because of a different study design, it is
difficult to compare their findings. Generally speaking,
hospital-based, nonrandom selection and single-screening
design tend to produce higher prevalence estimates. Our study
seems to show reasonably lower prevalence compared with the
Microalbuminuria Asian Prevalence and DEMAND Studies.
Theoretically, our survey should be a better representative of
the real MAU prevalence in Taiwan T2DM population. The
Shanghai study, using a population-based, randomized cluster
sampling and three screenings measured by radioimmuno-
assay (although without using conditional probability
approach), gave a very high prevalence of MAU in the
downtown citizens older than 30 years.11 In our survey, the
prevalence of MAU was 27.0% in T2DM patients aged 31e80
years. The Japanese study, which targeted an older (older than
40 years) general population in a nonrandom selection, single-
screening fashion, showed a relatively lower prevalence of
MAU of 13.7% (relatively half of the expected prevalence in
T2DM patients). In our survey, the prevalence of MAU was
27.5% in T2DM patients aged 41e80 years.
Obviously, using a single positive urinary screening test
will give a remarkably high FP rate for the diagnosis of MAU,
whereas adopting two positive out of three urinary screenings
reveals more conservative and accurate results. Our method in
this study of using a commercialized dipstick assay and
a simplified three-urine-screening process provide the conve-
nience of clinical practice and cost-effectiveness with more
reliable diagnosis of MAU. As far as prevention or interven-
tion in public health is concerned, our method can avoid
unnecessary cost and provide more reliable intervention
outcome measurements by reducing the huge FP rate (from
65.7% to 5.6%).
The prevalence of CKD Stage 3e5 (CKD Stage S3) in
Taiwan was reported as 6.9% from a national population-
based study12 and 7.13% from a national standard medical
screening program.13 In our hospital-based study, the preva-
lence of CKD StageS3 was 13.7% in T2DM patients, almosttwice that previously reported. A community-based study
among T2DM patients in Kinmen, Taiwan, also reported the
prevalence of CKD Stage S3 to be 15.1%.14 There are limi-
tations in our study, however. For example, the serum creati-
nine level was recorded within the latest 6 months from the
first screening, not exactly on the same day of recording of the
urine MAU level. For those with MAU or macroalbuminuria,
T2DM patients would have a 23.3% chance to be at CKD
Stage 3 or higher. Although the association between CKD
stage level and MAU or macroalbuminuria was significant, the
strength of the association needs to be confirmed by long-term
follow-up.
Concerning the issue of antihypertensive treatment in MAU
prevention, the GUARD Study reported that ACE inhibitor
with diuretic contributed a lot of albuminuria normalization
for T2DM patients with only MAU and hypertension.15 A
target blood pressure less than 130/80 mmHg in T2DM
patients was recommended by ADA.16 Furthermore, ACE
inhibitor or ARB regimen was recommended as an antihy-
pertensive therapy for T2DM patients with hypertension by
AHAeADA.17 In this study, drug usage data were collected
from the medical records within the latest 6 months before the
first visit, while all MAU patients were new diagnosed within
6 months after the first visit. Therefore, we could observe what
kind of drugs may have less frequency of MAU. Our results
showed that ACE inhibitor treatment group had the lowest
percentage of MAU, that is, 18.7%, but this finding did not
reach statistically significant level. The most frequent of the
two-drug combination therapy was ARB plus calcium channel
blockers; ACE inhibitor plus diuretic was the fourth in
frequency. Among patients without antihypertensive treat-
ment, there were still 49.2% with blood pressure greater than
the target level. The onset and detection of MAU represents
the diagnosis of early stage of diabetic nephropathy and
correlates with early stage of other diabetic complications,
such as diabetic autonomic neuropathy.18 Therefore, early
awareness and aggressive glycemic and blood pressure control
are warranted.19e21
In conclusion, this study demonstrates the application of
conditional probability method to justify the rationale for
adopting two positive out of three urinary screening tests for
the diagnosis of MAU. An adjusted prevalence rate of MAU as
26.9% is reported. These results may provide a basis for
costebenefit consideration in designing preventive and inter-
ventional policies in public health. Furthermore, these results
are associated with the need for strengthening and promoting
of the awareness and practice of early detection and moni-
toring of renal and cardiovascular risk factors in DM patients.
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